Published in J Leukoc Biol on April 13, 2006
Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. Clin Cancer Res (2015) 1.46
Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J Cell Biol (2009) 1.41
Moving towards a paradigm: common mechanisms of chemotactic signaling in Dictyostelium and mammalian leukocytes. Cell Mol Life Sci (2014) 1.15
Type I phosphatidylinositol 4-phosphate 5-kinase controls neutrophil polarity and directional movement. J Cell Biol (2007) 1.12
Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions. Mol Pharmacol (2010) 0.84
Pathway-selective suppression of chemokine receptor signaling in B cells by LPS through downregulation of PLC-β2. Cell Mol Immunol (2010) 0.82
Granulomatous response to Coxiella burnetii, the agent of Q fever: the lessons from gene expression analysis. Front Cell Infect Microbiol (2014) 0.82
Localization of phosphatidylinositol 4,5-bisphosphate to lipid rafts and uroids in the human protozoan parasite Entamoeba histolytica. Infect Immun (2013) 0.81
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. Immunology (2008) 0.80
Establishment and maintenance of cell polarity during leukocyte chemotaxis. Cell Adh Migr (2007) 0.80
HIV persistence: chemokines and their signalling pathways. Cytokine Growth Factor Rev (2012) 0.80
Impact of a dedicated neurocritical care team in treating patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care (2011) 1.77
Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology (2004) 1.54
Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol (2002) 1.46
Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer. Int J Cancer (2008) 1.39
Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest (2009) 1.35
Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: Role in osmoprotective transcriptional regulation. Proc Natl Acad Sci U S A (2006) 1.28
The role of 1α,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur J Immunol (2012) 1.27
The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci (2007) 1.26
Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology (2002) 1.25
Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol (2004) 1.10
Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. Trends Immunol (2007) 1.09
Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg Med Chem Lett (2010) 1.04
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev (2012) 1.03
The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol (2005) 1.01
Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J Immunol (2004) 0.99
Avoidable 30-day readmissions among patients with stroke and other cerebrovascular disease. Neurohospitalist (2012) 0.97
How does inflammation cause Barrett's metaplasia? Curr Opin Pharmacol (2009) 0.96
Optimal chemotactic responses of leukemic T cells to stromal cell-derived factor-1 requires the activation of both class IA and IB phosphoinositide 3-kinases. J Immunol (2003) 0.92
Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol (2006) 0.91
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology (2011) 0.90
TPL-2-mediated activation of MAPK downstream of TLR4 signaling is coupled to arginine availability. Sci Signal (2010) 0.89
PI3Kgamma is the dominant isoform involved in migratory responses of human T lymphocytes: effects of ex vivo maintenance and limitations of non-viral delivery of siRNA. Cell Signal (2007) 0.88
Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1. Org Biomol Chem (2011) 0.88
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology (2007) 0.88
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Curr Opin Pharmacol (2012) 0.88
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. J Leukoc Biol (2008) 0.85
Protein arginine methylation: a new handle on T lymphocytes? Trends Immunol (2010) 0.84
Subretinal hemorrhage from a peripapillary choroidal neovascular membrane in papilledema caused by idiopathic intracranial hypertension. J Neuroophthalmol (2006) 0.84
Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med (2009) 0.83
Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling. J Immunol Methods (2003) 0.83
Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility. J Immunol (2011) 0.83
PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs (2009) 0.83
Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities. Front Immunol (2012) 0.82
Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes. Cell Signal (2005) 0.82
Leukocyte navigation mechanisms as targets in airway diseases. Drug Discov Today (2006) 0.81
Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. Biochim Biophys Acta (2009) 0.80
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem (2013) 0.80
Toll-like receptors in the spotlight. Nat Immunol (2003) 0.79
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett (2007) 0.79
Evidence for PI3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells. Mol Immunol (2010) 0.78
New insights into mechanisms of gastrointestinal inflammation and cancer. Curr Opin Pharmacol (2009) 0.78
Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists. Bioorg Med Chem Lett (2009) 0.78
Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity. Anticancer Drugs (2008) 0.78
Chemokine receptors : therapeutic potential in asthma. Treat Respir Med (2006) 0.78
Genetic ablation of PI3Kγ results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. Eur J Immunol (2012) 0.78
7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett (2009) 0.78
ED, email, emess! Emerg Med J (2011) 0.77
Assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling: use of dominant negative mutants controlled by a tetracycline-regulated gene expression system. Methods Mol Biol (2004) 0.76
Mitochondrial superoxide generation enhances P2X7R-mediated loss of cell surface CD62L on naive human CD4+ T lymphocytes. J Immunol (2013) 0.76
Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol (2004) 0.76
Cell penetrating peptides fail to induce an innate immune response in epithelial cells in vitro: implications for continued therapeutic use. Eur J Pharm Biopharm (2013) 0.76
PI3K comes of age. Nat Immunol (2003) 0.75
Response to Medical Errors. Continuum (Minneap Minn) (2017) 0.75
890: STABILITY OF FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE AFTER PNEUMATIC TUBING. Crit Care Med (2016) 0.75
Spurs in the hunt for new immunomodulatory drug targets. Curr Opin Pharmacol (2012) 0.75
Status epilepticus following inhalational exposure to bifenthrin, a Type II pyrethroid. Clin Toxicol (Phila) (2013) 0.75
Quarantine, Isolation, and Health Care Workers. Continuum (Minneap Minn) (2015) 0.75
Design and synthesis of a library of chemokine antagonists. Bioorg Med Chem Lett (2011) 0.75
Determination of nickel species in stack emissions from eight residual oil-fired utility steam-generating units. Environ Sci Technol (2011) 0.75